Logo Image
  • News
  • Watch
  • Journals
  • Conferences
  • Events
  • Resources
  • CE
  • About AJMC
  • Subscribe
Opinion|Videos|September 30, 2024

Safety and Efficacy of HER2-Directed ADCs for NSCLC

Panelists discuss how the selection between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine is guided by findings from pivotal trials like DESTINY-Lung01 and DESTINY-Lung02, real-world patient outcomes compared with clinical trial results, and the management of common treatment-related adverse events associated with these HER2-directed therapies.

Episodes in this series

Video content above is prompted by the following:

  • What factors guide the choice between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine?
  • What key insights emerged from pivotal trials like the phase 2 basket DESTINY-Lung01and DESTINY-Lung02?
  • How do real-world patient outcomes compare with those seen in clinical trials?
  • What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?

Related Content